News und Analysen
DGAP-News: NanoRepro AG: Hauptversammlung mit Dividendenvorschlag
DGAP-News: NanoRepro AG: Hauptversammlung mit Dividendenvorschlag
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
DGAP-News: CytoTools AG: Update zu Stand der Verhandlungen zwischen CytoTools AG und DermaTools Biotech GmbH - Klagebedingte Verzögerung bei der Durchführung der Kapitalerhöhung
DGAP-News: CytoTools AG: Update zu Stand der Verhandlungen zwischen CytoTools AG und DermaTools Biotech GmbH - Klagebedingte Verzögerung bei der Durchführung der Kapitalerhöhung
DGAP-Adhoc: CytoTools AG: Anfechtungsklage gegen Hauptversammlungsbeschlüsse vom 22.12.2021 erhoben
DGAP-Adhoc: CytoTools AG: Anfechtungsklage gegen Hauptversammlungsbeschlüsse vom 22.12.2021 erhoben
Pharnext appoints Valérie Worrall as Chief Financial Officer
Pharnext appoints Valérie Worrall as Chief Financial Officer
DGAP-News: Burcon NutraScience Corp.: Burcon meldet Ergebnisse für drittes Quartal des Geschäftsjahrs 2022
DGAP-News: Burcon NutraScience Corp.: Burcon meldet Ergebnisse für drittes Quartal des Geschäftsjahrs 2022
DGAP-News: Burcon NutraScience Corp.: Burcon Reports Fiscal 2022 Third Quarter Results
DGAP-News: Burcon NutraScience Corp.: Burcon Reports Fiscal 2022 Third Quarter Results
DGAP-News: NanoRepro AG: NanoRepro AG: Vergleichende Studie von renommierter Universität abgeschlossen. Viromed / NanoRepro detektiert Omikron
DGAP-News: NanoRepro AG: NanoRepro AG: Vergleichende Studie von renommierter Universität abgeschlossen. Viromed / NanoRepro detektiert Omikron
DGAP-News: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
DGAP-News: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
DGAP-News: Heidelberg Pharma gibt Dosierung des ersten Patienten mit dem Antikörper-Amanitin-Konjugat HDP-101 im Multiplen Myelom bekannt
DGAP-News: Heidelberg Pharma gibt Dosierung des ersten Patienten mit dem Antikörper-Amanitin-Konjugat HDP-101 im Multiplen Myelom bekannt
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
DGAP-News: Burcon NutraScience Corp.: Burcon kündigt für 14. Februar 2022 Konferenzgespräch über drittes Quartal 2022 an
DGAP-News: Burcon NutraScience Corp.: Burcon kündigt für 14. Februar 2022 Konferenzgespräch über drittes Quartal 2022 an
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Third Quarter Conference Call to be Held on February 14, 2022
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Third Quarter Conference Call to be Held on February 14, 2022
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
EQS-Adhoc: Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
EQS-Adhoc: Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
EQS-Adhoc: Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Expansion of Intellectual Property Portfolio
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Expansion of Intellectual Property Portfolio
DGAP-News: Burcon NutraScience Corp.: Burcon kündigt Erweiterung des Portfolios an geistigem Eigentum an
DGAP-News: Burcon NutraScience Corp.: Burcon kündigt Erweiterung des Portfolios an geistigem Eigentum an
EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
EQS-Adhoc: Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
DGAP-News: NanoRepro AG: 94,1 % statt 76,5 % - Handelsblatt korrigiert Sensitivität des NanoRepro Schnelltests nach oben
DGAP-News: NanoRepro AG: 94,1 % statt 76,5 % - Handelsblatt korrigiert Sensitivität des NanoRepro Schnelltests nach oben
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
EQS-Adhoc: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx
EQS-Adhoc: Relief Comments on Lawsuit Filed Against It by NeuroRx